Closed · PAS-25-161 · CFDA 93.273 · Discretionary

HIV Prevention and Alcohol (R34 Clinical Trials Optional)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $450K
Award range
Closed
Status
May 7, 2026
Close date
-
Expected awards

The verdict

HIV Prevention and Alcohol (R34 Clinical Trials Optional) is a closed discretionary listing from National Institutes of Health that offered Up to $450,000. Future funding cycles may be published under the same CFDA number.

up to $450K
award range
Closed
application status
93.273
CFDA program

Opportunity snapshot. This Grants.gov announcement - HIV Prevention and Alcohol (R34 Clinical Trials Optional) - is cataloged under number PAS-25-161 and tied to CFDA assistance listing 93.273, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on November 25, 2024. The funding category is Discretionary, delivered as a grant.

Award economics. The award range on file is Up to $450,000. The agency has projected $225,000 in total estimated funding for this announcement. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.

Deadline and action path. This opportunity closed on May 7, 2026. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.

Award Range

Up to $450,000

Close Date

May 7, 2026

Posted

November 25, 2024

Est. Total Funding

$225,000

Instrument

Grant

Description

The NOFO seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This R34 Notice of Funding Opportunity (NOFO) supports studies that are both necessary and sufficient to inform the planning of a clinical trial within the scope of the companion announcement HIV Prevention and Alcohol (R01 Clinical Trials Optional). The NIAAA expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention of HIV. In this NIAAA funding opportunity for pilot clinical trials the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a clinical trial and testing of intervention tools.

Eligibility

Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH Grants Information grantsinfo@nih.gov

Key Dates

Posted November 25, 2024
Close Date May 7, 2026
Archive Date June 12, 2026
Last Updated November 25, 2024

Frequently Asked Questions

What is this grant opportunity?
This is a federal funding opportunity titled "HIV Prevention and Alcohol (R34 Clinical Trials Optional)", offered by National Institutes of Health. It is associated with CFDA program 93.273. The NOFO seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HI...
Is this opportunity still open?
No, this opportunity is closed. It closed on May 7, 2026. Check the parent program page for future funding cycles.
How much funding is available?
The award range for this opportunity is Up to $450,000. Total estimated funding: $225,000.
How do I apply?
Applications for federal grant opportunities are typically submitted through Grants.gov. Visit the official listing at grants.gov for application instructions, required documents, and submission deadlines.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants Editorial